Related Experiment Video

Updated: Jul 12, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Increased mortality with FLA compared with ADE chemotherapy in high-risk AML

Steven W Lane, Paula Marlton, Peter N Mollee

    Blood
    |November 23, 2006
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
    07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
    04:36

    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

    Published on: October 17, 2025

    Related Experiment Videos

    Last Updated: Jul 12, 2026

    Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
    14:51

    Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

    Published on: June 17, 2022

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
    07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
    04:36

    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

    Published on: October 17, 2025

    Related Concept Videos

    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

    Articles linked to this work by shared authors, journal, and citation graph.

    Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

    Internal medicine journal·2026

    LOTR-Seq: A protocol for large-scale simultaneous single-cell long-read genotyping of transcripts.

    STAR protocols·2026

    Homozygous kinase-dead Csf1r mutation in outbred mice reveals essential and redundant functions of tissue resident macrophages.

    Journal of leukocyte biology·2026

    Single-cell long-read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML.

    Blood advances·2026

    Dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy.

    British journal of haematology·2026

    Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study.

    Med (New York, N.Y.)·2025

    Measurable Residual Disease-Dependent Unfavorable Outcomes in Pediatric PAX5-Rearranged B-Acute Lymphoblastic Leukemia.

    Blood·2026

    The hepatic FGFR-ERK-HRG axis regulates heparin-induced thrombocytopenia with thrombosis.

    Blood·2026

    HOW I TREAT BLEEDING IN WOMEN AND GIRLS WITH HEMOPHILIA/ HEMOPHILIA CARRIERS.

    Blood·2026

    FERMT3 alternative splicing enhances kindlin-3 membrane recruitment for neutrophil adhesion during stress myelopoiesis.

    Blood·2026

    Risk of recurrence in patients with provoked venous thromboembolism: a prospective cohort study.

    Blood·2026

    How I treat autoimmune neutropenia in adults.

    Blood·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us